Home Stock

Stock Research: C4 Therapeutics

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

C4 Therapeutics

NSQ:CCCC US12529R1077
40
  • Value
    51
  • Growth
    60
  • Safety
    Safety
    16
  • Combined
    37
  • Sentiment
    49
  • 360° View
    360° View
    40
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

more

ANALYSIS: With an Obermatt 360° View of 40 (better than 40% compared with alternatives), overall professional sentiment and financial characteristics for the stock C4 Therapeutics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for C4 Therapeutics. The consolidated Value Rank has an attractive rank of 51, which means that the share price of C4 Therapeutics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 51% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 60, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 49. Professional investors are more confident in 51% other stocks. Worryingly, the company has risky financing, with a Safety rank of 16. This means 84% of comparable companies have a safer financing structure than C4 Therapeutics. ...read more

more
Strongest Rank Market Pulse
Weakest Rank Analyst Opinions
Country USA
Industry Biotechnology
Size Small
Website c4therapeutics.com
Index
NASDAQ
C4 Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
51 n/a n/a n/a
Growth
60 n/a n/a n/a
Safety
Safety
16 n/a n/a n/a
Sentiment
49 n/a n/a n/a
360° View
360° View
40 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
78 n/a n/a n/a
Opinions Change
50 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
6 n/a n/a n/a
Sentiment
49 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
51 n/a n/a n/a
Growth
60 n/a n/a n/a
Safety Safety
16 n/a n/a n/a
Combined
37 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
52 n/a n/a n/a
Price vs. Earnings (P/E)
19 n/a n/a n/a
Price vs. Book (P/B)
62 n/a n/a n/a
Dividend Yield
n/a n/a n/a n/a
Value
51 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
14 n/a n/a n/a
Profit Growth
58 n/a n/a n/a
Capital Growth
72 n/a n/a n/a
Stock Returns
64 n/a n/a n/a
Growth
60 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
32 n/a n/a n/a
Refinancing
27 n/a n/a n/a
Liquidity
35 n/a n/a n/a
Safety Safety
16 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to C4 Therapeutics and broaden your portfolio horizons.

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

Keurig Dr Pepper

NSQ:KDP
Country: USA
Industry: Soft Drinks
Size: X-Large
Full Stock Analysis

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a mixed bag with good value and high growth balanced by risky financing and negative sentiment. This is a risky stock that requires conviction; you should only consider it if you are willing to conduct further research into the underlying sentiment and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews